Two major pathways of penile carcinogenesis are known: human papillomavirus (HPV)-induced penile cancer and HPV-negative cancers associated with chronic dermatoses. Therefore, modern measures for prevention of penile cancer may for example include prophylactic HPV vaccination. The resulting B‑cell-mediated immunity to HPV capsid proteins is effective protection against future HPV infections. Contrarily when treating existing HPV infections or HPV-associated cancers an antigen-specific T‑cell immunity is necessary. To date, screening and treatment of precancerous lesions to prevent penile cancer are not established in the German health care program and the highly expected therapeutic HPV vaccines are still on the horizon. In this article, we focus on possible strategies to prevent HPV-related penile cancer on different levels of carcinogenesis.
Der Urologe. Ausg. A. 2018 Feb 26 [Epub ahead of print]
P Schneede, B Schlenker
Urologische Klinik, Klinikum Memmingen, Bismarckstraße 23, 87700, Memmingen, Deutschland. ., Klinikum der Universität München, Großhadern, München, Deutschland.